+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

  • PDF Icon

    Report

  • 195 Pages
  • June 2021
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5354455
Description Jump to:
The Global Erythropoietin Drugs Market size is expected to reach $20.2 billion by 2027, rising at a market growth of 11.8% CAGR during the forecast period. Erythropoietin (EPO) also called hematopoietin is a glycoprotein hormone. It stimulates the process of erythropoiesis which results in the production of red blood cells in the bone marrow. The main goal for the development of erythropoietin drug was to treat anaemic conditions arising from end-stage renal disease (ESRD) disease. Thus, it helps in treatments of this disease and dialysis procedures. Apart from its use in ESRD anaemic conditions, erythropoietin drugs also received approvals for chemotherapy-induced anaemia. The post-abbreviated new drug application (ANDA) is getting approvals and there is a high success rate of erythropoietin drugs in chemotherapy-induced anaemia. Due to all these factors, major biopharmaceutical companies turned their focus towards another form of induced anaemia, that is ART-induced anaemia which occurs mostly among the HIV patients.

Epoetin alfa (Epoge) is a kind of recombinant erythropoietin that was developed by Amgen Inc. in 1983. It was the first rhEPO that was commercialized in the United States, after alfa and beta formulations. Epoetin refers to an erythropoiesis-stimulating glycoprotein that is composed of a 165-amino acid. It is produced in cell culture based on recombinant DNA technology. This drug is used to treat patients suffering from anaemia and other blood-related clinical conditions like chronic renal failure, chemotherapy, and antiviral drug therapy. This drug is also recommended for patients who are at high risk for perioperative blood loss due to surgical procedures.



COVID-19 Impact

The COVID-19 resulted in the disruption of workflows in the health care sector across the world. A number of industries were forced to go for shutdown temporarily due to this outbreak. The main affected industry is the sub-domains of health care. Yet, it has positively affected the demand for medicines and increased the demand for several medical services, such as erythropoietin. The erythropoietin (EPO) drug is used to treat anaemia and works effectively against COVID-19. This has been scientifically proved by scientists of the Max Planck Institute of Experimental Medicine in Göttingen. According to the research, the SARS-CoV-2 potentially attacks the brain, and erythropoietin can diminish serious disease development. Thus, it can protect people from the development of long-term neurological problems.

However, EPO is beneficial in many other diseases and has cytoprotective effects such as regenerative, anti-ischemic, and anti-apoptotic effects in tissues like lung, kidney, cardiac muscle, retina, pancreas, nervous system, and endothelial cells. Therefore, the impact of the COVID-19 pandemic is likely to have a positive impact on the erythropoietin drug market.

Drug Class Outlook

Based on Drug Class, the market is segmented into Biologics and Biosimilars. Based on Drug Class, the biologics erythropoietin segment dominated the market in 2020 because of the patent protection. Other factors driving the growth of this segment include the presence of a large patient population and increased uptake of biologics in various diseases. The availability of very few biologics in the market resulted in higher adoption of this drug.

Product Outlook

Based on Product, the market is segmented into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others. Epoetin-beta is a recombinant type of drug formed from epoetin-alfa. This product segment is growing owing to its benefits like improved efficacy and a longer half-life compared to the epoetin-alfa. Darbepoetin-alfa is also a novel erythropoietin drug. It is developed by Amgen, Inc., marketed under the brand name Aranesp. Darbepoetin-alfa segment is likely to see positive growth during the forecast period. It is accredited to its higher efficacy, cost-effectiveness, and longer half-life. It is considered a feasible solution for the treatment of anaemia arising due to end-stage renal diseases.



Application Outlook

Based on Application, the market is segmented into Renal Diseases, Cancer, Hematology and Neurology. The cancer segment is expected to showcase fastest growth rate during the forecast period. It is due to the increasing cases of cancer incidence across the world. Cancer chemotherapy includes the utilization of medication which is capable of increasing the RBC count amongst patients. Thus, the usage of such drugs for chemotherapy has gained considerable attention in recent years. This has increased the demand for EPO drugs for cancer treatment that will act as a positive factor to augment the growth of this segment.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as one of the dominating regions of the global market by. It is accredited to the factors like the increasing incidence of chronic diseases including cancer, CKD, and HIV. As per data by the Centers for Disease Control and Prevention (CDC), there are 1.2 million people in the U.S. who are living with HIV and more than 39,000 cases were detected in 2015. These statistics are a clear indication that the demand for EPO drugs will increase over the forecast period.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.

Scope of the Study

Market Segments covered in the Report:

By Drug Class
  • Biologics
  • Biosimilars

By Product
  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • others

By Application
  • Renal Diseases
  • Cancer
  • Hematology
  • Neurology

By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled
  • Johnson and Johnson
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Biocon Limited
  • Intas Pharmaceutical Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • LG Corporation (LG Life Sciences Ltd.)
  • Celltrion, Inc.

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Erythropoietin Drugs Market, by Drug Class
1.4.2 Global Erythropoietin Drugs Market, by Product
1.4.3 Global Erythropoietin Drugs Market, by Application
1.4.4 Global Erythropoietin Drugs Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Erythropoietin Drugs Market by Drug Class
3.1 Global Biologics Market by Region
3.2 Global Biosimilars Market by Region
Chapter 4. Global Erythropoietin Drugs Market by Product
4.1 Global Epoetin-alfa Market by Region
4.2 Global Epoetin-beta Market by Region
4.3 Global Darbepoetin-alfa Market by Region
4.4 Global Other Product Market by Region
Chapter 5. Global Erythropoietin Drugs Market by Application
5.1 Global Renal Diseases Market by Region
5.2 Global Cancer Market by Region
5.3 Global Hematology Market by Region
5.4 Global Neurology Market by Region
Chapter 6. Global Erythropoietin Drugs Market by Region
6.1 North America Erythropoietin Drugs Market
6.1.1 North America Erythropoietin Drugs Market by Drug Class
6.1.1.1 North America Biologics Market by Country
6.1.1.2 North America Biosimilars Market by Country
6.1.2 North America Erythropoietin Drugs Market by Product
6.1.2.1 North America Epoetin-alfa Market by Country
6.1.2.2 North America Epoetin-beta Market by Country
6.1.2.3 North America Darbepoetin-alfa Market by Country
6.1.2.4 North America Other Product Market by Country
6.1.3 North America Erythropoietin Drugs Market by Application
6.1.3.1 North America Renal Diseases Market by Country
6.1.3.2 North America Cancer Market by Country
6.1.3.3 North America Hematology Market by Country
6.1.3.4 North America Neurology Market by Country
6.1.4 North America Erythropoietin Drugs Market by Country
6.1.4.1 US Erythropoietin Drugs Market
6.1.4.1.1 US Erythropoietin Drugs Market by Drug Class
6.1.4.1.2 US Erythropoietin Drugs Market by Product
6.1.4.1.3 US Erythropoietin Drugs Market by Application
6.1.4.2 Canada Erythropoietin Drugs Market
6.1.4.2.1 Canada Erythropoietin Drugs Market by Drug Class
6.1.4.2.2 Canada Erythropoietin Drugs Market by Product
6.1.4.2.3 Canada Erythropoietin Drugs Market by Application
6.1.4.3 Mexico Erythropoietin Drugs Market
6.1.4.3.1 Mexico Erythropoietin Drugs Market by Drug Class
6.1.4.3.2 Mexico Erythropoietin Drugs Market by Product
6.1.4.3.3 Mexico Erythropoietin Drugs Market by Application
6.1.4.4 Rest of North America Erythropoietin Drugs Market
6.1.4.4.1 Rest of North America Erythropoietin Drugs Market by Drug Class
6.1.4.4.2 Rest of North America Erythropoietin Drugs Market by Product
6.1.4.4.3 Rest of North America Erythropoietin Drugs Market by Application
6.2 Europe Erythropoietin Drugs Market
6.2.1 Europe Erythropoietin Drugs Market by Drug Class
6.2.1.1 Europe Biologics Market by Country
6.2.1.2 Europe Biosimilars Market by Country
6.2.2 Europe Erythropoietin Drugs Market by Product
6.2.2.1 Europe Epoetin-alfa Market by Country
6.2.2.2 Europe Epoetin-beta Market by Country
6.2.2.3 Europe Darbepoetin-alfa Market by Country
6.2.2.4 Europe Other Product Market by Country
6.2.3 Europe Erythropoietin Drugs Market by Application
6.2.3.1 Europe Renal Diseases Market by Country
6.2.3.2 Europe Cancer Market by Country
6.2.3.3 Europe Hematology Market by Country
6.2.3.4 Europe Neurology Market by Country
6.2.4 Europe Erythropoietin Drugs Market by Country
6.2.4.1 Germany Erythropoietin Drugs Market
6.2.4.1.1 Germany Erythropoietin Drugs Market by Drug Class
6.2.4.1.2 Germany Erythropoietin Drugs Market by Product
6.2.4.1.3 Germany Erythropoietin Drugs Market by Application
6.2.4.2 UK Erythropoietin Drugs Market
6.2.4.2.1 UK Erythropoietin Drugs Market by Drug Class
6.2.4.2.2 UK Erythropoietin Drugs Market by Product
6.2.4.2.3 UK Erythropoietin Drugs Market by Application
6.2.4.3 France Erythropoietin Drugs Market
6.2.4.3.1 France Erythropoietin Drugs Market by Drug Class
6.2.4.3.2 France Erythropoietin Drugs Market by Product
6.2.4.3.3 France Erythropoietin Drugs Market by Application
6.2.4.4 Russia Erythropoietin Drugs Market
6.2.4.4.1 Russia Erythropoietin Drugs Market by Drug Class
6.2.4.4.2 Russia Erythropoietin Drugs Market by Product
6.2.4.4.3 Russia Erythropoietin Drugs Market by Application
6.2.4.5 Spain Erythropoietin Drugs Market
6.2.4.5.1 Spain Erythropoietin Drugs Market by Drug Class
6.2.4.5.2 Spain Erythropoietin Drugs Market by Product
6.2.4.5.3 Spain Erythropoietin Drugs Market by Application
6.2.4.6 Italy Erythropoietin Drugs Market
6.2.4.6.1 Italy Erythropoietin Drugs Market by Drug Class
6.2.4.6.2 Italy Erythropoietin Drugs Market by Product
6.2.4.6.3 Italy Erythropoietin Drugs Market by Application
6.2.4.7 Rest of Europe Erythropoietin Drugs Market
6.2.4.7.1 Rest of Europe Erythropoietin Drugs Market by Drug Class
6.2.4.7.2 Rest of Europe Erythropoietin Drugs Market by Product
6.2.4.7.3 Rest of Europe Erythropoietin Drugs Market by Application
6.3 Asia Pacific Erythropoietin Drugs Market
6.3.1 Asia Pacific Erythropoietin Drugs Market by Drug Class
6.3.1.1 Asia Pacific Biologics Market by Country
6.3.1.2 Asia Pacific Biosimilars Market by Country
6.3.2 Asia Pacific Erythropoietin Drugs Market by Product
6.3.2.1 Asia Pacific Epoetin-alfa Market by Country
6.3.2.2 Asia Pacific Epoetin-beta Market by Country
6.3.2.3 Asia Pacific Darbepoetin-alfa Market by Country
6.3.2.4 Asia Pacific Other Product Market by Country
6.3.3 Asia Pacific Erythropoietin Drugs Market by Application
6.3.3.1 Asia Pacific Renal Diseases Market by Country
6.3.3.2 Asia Pacific Cancer Market by Country
6.3.3.3 Asia Pacific Hematology Market by Country
6.3.3.4 Asia Pacific Neurology Market by Country
6.3.4 Asia Pacific Erythropoietin Drugs Market by Country
6.3.4.1 China Erythropoietin Drugs Market
6.3.4.1.1 China Erythropoietin Drugs Market by Drug Class
6.3.4.1.2 China Erythropoietin Drugs Market by Product
6.3.4.1.3 China Erythropoietin Drugs Market by Application
6.3.4.2 Japan Erythropoietin Drugs Market
6.3.4.2.1 Japan Erythropoietin Drugs Market by Drug Class
6.3.4.2.2 Japan Erythropoietin Drugs Market by Product
6.3.4.2.3 Japan Erythropoietin Drugs Market by Application
6.3.4.3 India Erythropoietin Drugs Market
6.3.4.3.1 India Erythropoietin Drugs Market by Drug Class
6.3.4.3.2 India Erythropoietin Drugs Market by Product
6.3.4.3.3 India Erythropoietin Drugs Market by Application
6.3.4.4 South Korea Erythropoietin Drugs Market
6.3.4.4.1 South Korea Erythropoietin Drugs Market by Drug Class
6.3.4.4.2 South Korea Erythropoietin Drugs Market by Product
6.3.4.4.3 South Korea Erythropoietin Drugs Market by Application
6.3.4.5 Singapore Erythropoietin Drugs Market
6.3.4.5.1 Singapore Erythropoietin Drugs Market by Drug Class
6.3.4.5.2 Singapore Erythropoietin Drugs Market by Product
6.3.4.5.3 Singapore Erythropoietin Drugs Market by Application
6.3.4.6 Malaysia Erythropoietin Drugs Market
6.3.4.6.1 Malaysia Erythropoietin Drugs Market by Drug Class
6.3.4.6.2 Malaysia Erythropoietin Drugs Market by Product
6.3.4.6.3 Malaysia Erythropoietin Drugs Market by Application
6.3.4.7 Rest of Asia Pacific Erythropoietin Drugs Market
6.3.4.7.1 Rest of Asia Pacific Erythropoietin Drugs Market by Drug Class
6.3.4.7.2 Rest of Asia Pacific Erythropoietin Drugs Market by Product
6.3.4.7.3 Rest of Asia Pacific Erythropoietin Drugs Market by Application
6.4 LAMEA Erythropoietin Drugs Market
6.4.1 LAMEA Erythropoietin Drugs Market by Drug Class
6.4.1.1 LAMEA Biologics Market by Country
6.4.1.2 LAMEA Biosimilars Market by Country
6.4.2 LAMEA Erythropoietin Drugs Market by Product
6.4.2.1 LAMEA Epoetin-alfa Market by Country
6.4.2.2 LAMEA Epoetin-beta Market by Country
6.4.2.3 LAMEA Darbepoetin-alfa Market by Country
6.4.2.4 LAMEA Other Product Market by Country
6.4.3 LAMEA Erythropoietin Drugs Market by Application
6.4.3.1 LAMEA Renal Diseases Market by Country
6.4.3.2 LAMEA Cancer Market by Country
6.4.3.3 LAMEA Hematology Market by Country
6.4.3.4 LAMEA Neurology Market by Country
6.4.4 LAMEA Erythropoietin Drugs Market by Country
6.4.4.1 Brazil Erythropoietin Drugs Market
6.4.4.1.1 Brazil Erythropoietin Drugs Market by Drug Class
6.4.4.1.2 Brazil Erythropoietin Drugs Market by Product
6.4.4.1.3 Brazil Erythropoietin Drugs Market by Application
6.4.4.2 Argentina Erythropoietin Drugs Market
6.4.4.2.1 Argentina Erythropoietin Drugs Market by Drug Class
6.4.4.2.2 Argentina Erythropoietin Drugs Market by Product
6.4.4.2.3 Argentina Erythropoietin Drugs Market by Application
6.4.4.3 UAE Erythropoietin Drugs Market
6.4.4.3.1 UAE Erythropoietin Drugs Market by Drug Class
6.4.4.3.2 UAE Erythropoietin Drugs Market by Product
6.4.4.3.3 UAE Erythropoietin Drugs Market by Application
6.4.4.4 Saudi Arabia Erythropoietin Drugs Market
6.4.4.4.1 Saudi Arabia Erythropoietin Drugs Market by Drug Class
6.4.4.4.2 Saudi Arabia Erythropoietin Drugs Market by Product
6.4.4.4.3 Saudi Arabia Erythropoietin Drugs Market by Application
6.4.4.5 South Africa Erythropoietin Drugs Market
6.4.4.5.1 South Africa Erythropoietin Drugs Market by Drug Class
6.4.4.5.2 South Africa Erythropoietin Drugs Market by Product
6.4.4.5.3 South Africa Erythropoietin Drugs Market by Application
6.4.4.6 Nigeria Erythropoietin Drugs Market
6.4.4.6.1 Nigeria Erythropoietin Drugs Market by Drug Class
6.4.4.6.2 Nigeria Erythropoietin Drugs Market by Product
6.4.4.6.3 Nigeria Erythropoietin Drugs Market by Application
6.4.4.7 Rest of LAMEA Erythropoietin Drugs Market
6.4.4.7.1 Rest of LAMEA Erythropoietin Drugs Market by Drug Class
6.4.4.7.2 Rest of LAMEA Erythropoietin Drugs Market by Product
6.4.4.7.3 Rest of LAMEA Erythropoietin Drugs Market by Application
Chapter 7. Company Profiles
7.1 Johnson and Johnson
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental &Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals:
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Amgen, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.1 Financial Analysis
7.4.2 Segmental and Regional Analysis
7.4.3 Research & Development Expense
7.5 Biocon Limited
7.5.1 Company Overview
7.6 Intas Pharmaceutical Ltd.
7.6.1 Company Overview
7.7 Sun Pharmaceutical Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 Dr. Reddy's Laboratories Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 LG Corporation (LG Life Sciences Ltd.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.10. Celltrion, Inc.
7.10.1 Company Overview

Companies Mentioned

  • Johnson and Johnson
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Biocon Limited
  • Intas Pharmaceutical Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • LG Corporation (LG Life Sciences Ltd.)
  • Celltrion, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Erythropoietin Drugs Market - Forecasts from 2024 to 2029 - Product Image

Erythropoietin Drugs Market - Forecasts from 2024 to 2029

  • Report
  • 143 Pages
  • Global
From
Erythropoietin Drugs Market Report by Drug Class, Product Type, Application, End-User, and Region 2024-2032 - Product Image

Erythropoietin Drugs Market Report by Drug Class, Product Type, Application, End-User, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From
Erythropoietin (EPO) Global Market Report 2024 - Product Image

Erythropoietin (EPO) Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Erythropoietin Drugs - Global Strategic Business Report - Product Image

Erythropoietin Drugs - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Erythropoietin Stimulating Agents Market by Product Type, Application, End-user, Mode of Administration, Target Patient Type, Manufacturing Process, Pricing Strategy, Treatment Duration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Erythropoietin Stimulating Agents Market by Product Type, Application, End-user, Mode of Administration, Target Patient Type, Manufacturing Process, Pricing Strategy, Treatment Duration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.